Regnan investors are helping create low-cost tests to fight disease

Regnan’s Global Equity Impact Solutions Fund invests in mission-driven companies we believe are well placed to solve the world’s biggest problems.

This is the story of one of those companies, molecular diagnostics innovator QIAGEN.

 

LABORATORY and diagnostic tests influence 70 per cent of medical decisions — but account for only 2 to 5 per cent of healthcare spending, the US Health Industry Distributors Association reports.

Greater diagnostic testing could save $900 million in annual healthcare costs in the US alone, the association estimates.

In poor and middle-income countries lack of diagnostic testing is even more serious.

Some 1.5 million people died of tuberculosis in 2018 — a number that would be much smaller if the disease was identified earlier according to the World Health Organisation.

Two-thirds of cases were in eight emerging economies.

Qiagen offers innovative testing solutions

Regnan’s impact investment team aims to outperform the broad global equity market over the long term by investing in companies that provide solutions for the world’s growing sustainability needs.

One of those companies is Netherlands-based Qiagen.

Qiagen makes molecular testing equipment and consumables for a global customer base.

Molecular diagnostics enables researchers and clinicians to quickly use biological samples to diagnose and monitor diseases, assess patient health and decide which therapies work best.

Qiagen’s molecular testing products diagnose a wide range of conditions, including tuberculosis, influenza, HIV and hospital infections. They are designed for use without requiring sophisticated expertise.

The biotech leader has also developed a number of products to help healthcare professionals quickly identify COVID-19.

For example this video shows a Qiagen solution that can prepare a sample in only two minutes to deliver results under one hour:

Qiagen has also leveraged its product philosophy to expand beyond its mainstay of infectious diseases into immune disorders and prenatal and neonatal health.

For example, the business is soon to launch a low-cost version of its revolutionary diagnostic test for latent tuberculosis detection, QuantiFERON-TB Gold.

This will make the test available for the first time in poor countries with a high incidence rate and a lack of laboratories.

Qiagen is also ramping up production of its comprehensive Covid-19 diagnostics portfolio. It is the world’s leading provider of RNA extraction kits, used as inputs for PCR tests, which detect active infections.

Qiagen’s competitive position

Leadership in technology and innovation – particularly in molecular diagnostics — differentiates Qiagen.

In the global struggle to increase and improve global diagnostics capabilities, Qiagen has achieved breakthroughs.

It has also contributed through improving the speed, accuracy and accessibility of existing diagnostic products.

Qiagen helps solve the world’s biggest problems

Regnan identifies companies such as Qiagen using the 17 United Nations Sustainable Development Goals (SDGs) and their 169 underlying targets as an investment lens.

The SDGs are a 15-year plan to end poverty, protect the planet and improve the lives and prospects of everyone, everywhere.

In 2019 the UN called for “a decade of ambitious action to deliver the goals by 2030.

“Evidence shows that investing in the SDGs makes economic sense, with estimates highlighting that achieving the SDGs could open up US$12 trillion of market opportunities and create 380 million new jobs,” the UN says.

Drawing on the SDGs and their targets, Regnan’s investment team has built a comprehensive, proprietary investment framework – the Regnan SDG Taxonomy.

Qiagen’s activities contribute to three SDG targets for 2030:

  • SDG target 2: End preventable deaths of newborns and children under 5 years of age, with all countries aiming to reduce neonatal mortality to at least as low as 12 per 1000 live births and under-5 mortality to at least as low as 25 per 1000 live births
  • SDG target 3: End the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases and combat hepatitis, water-borne diseases and other communicable diseases
  • SDG target 4: Reduce by one third premature mortality from non-communicable diseases through prevention and treatment and promote mental health and well-being

 

Find out more

Regnan is a responsible investment leader with a long and proud history of providing insight and advice to investors with an interest in long-term, broad-based or values-aligned performance.

For more than 20 years our pioneering analysis has changed the way investors and businesses think about value creation and their wider responsibilities to society.

Building on that expertise, in 2019 Regnan expanded into responsible investment funds management, backed by the considerable resources of Pendal Group.

The Regnan Global Equity Impact Solutions Fund invests in mission-driven companies we believe are well placed to solve the world’s biggest problems.

Managed by a four-person investment team based in London, the fund aims to outperform the broad global equity market over the long term by investing in companies that provide solutions for the growing, unmet sustainability needs of society and the environment.

Regnan Global Equity Impact Solutions Fund is distributed in Australia by Pendal and in the UK and Europe by J O Hambro.

Australian investors: Contact Jeremy Dean at Jeremy.Dean@Regnan.com

Information for UK, European and other international investors: www.regnan-johcm.com

This article has been prepared by Pendal Fund Services Limited (PFSL) ABN 13 161 249 332, AFSL No 431426 and the information contained within is current as at 27 November 2020. It is not to be published, or otherwise made available to any person other than the party to whom it is provided.

PFSL is the responsible entity and issuer of units in the Regnan Global Equity Impact Solutions Fund (Fund) ARSN: 645 981 853. A product disclosure statement (PDS) is available for the Fund and can be obtained by calling 1800 813 886 or visiting www.pendalgroup.com. You should obtain and consider the PDS before deciding whether to acquire, continue to hold or dispose of units in the Fund. An investment in the Fund is subject to investment risk, including possible delays in repayment of withdrawal proceeds and loss of income and principal invested.

This article is for general information purposes only, should not be considered as a comprehensive statement on any matter and should not be relied upon as such. It has been prepared without taking into account any recipient’s personal objectives, financial situation or needs. Because of this, recipients should, before acting on this information, consider its appropriateness having regard to their individual objectives, financial situation and needs. This information is not to be regarded as a securities recommendation.

The information in this article may contain material provided by third parties, is given in good faith and has been derived from sources believed to be accurate as at its issue date. While such material is published with necessary permission, and while all reasonable care has been taken to ensure that the information in this article is complete and correct, to the maximum extent permitted by law neither PFSL nor any company in the Pendal group accepts any responsibility or liability for the accuracy or completeness of this information.

Performance figures are calculated in accordance with the Financial Services Council (FSC) standards. Performance data (post-fee) assumes reinvestment of distributions and is calculated using exit prices, net of management costs. Performance data (pre-fee) is calculated by adding back management costs to the post-fee performance. Past performance is not a reliable indicator of future performance.

Any projections contained in this article are predictive and should not be relied upon when making an investment decision or recommendation. While we have used every effort to ensure that the assumptions on which the projections are based are reasonable, the projections may be based on incorrect assumptions or may not take into account known or unknown risks and uncertainties. The actual results may differ materially from these projections.